Detail akcie Natera online

Business Summary: Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Natera Inc revenues increased 34% to $1.64B. Net loss increased 87% to $255.4M. Revenues reflect Insurance carriers segment increase of 37% to $1.55B, Patients segment increase of 15% to $23.4M, United States segment increase of 35% to $1.61B. Higher net loss reflects Selling, general and administrative increase of 52% to $729.8M (expense).